

The board of directors' statement under Chapter 19 Section 22 of the Companies Act – Medicover AB (publ)

The board of directors of Medicover AB (publ) has proposed that the annual general meeting to be held on 30 April 2020 resolves to authorise the board of directors to resolve to acquire own class C shares of Medicover AB (publ). The board of directors considers, in view of what is stated below, that the proposed authorisation for the board of directors to resolve to acquire own shares is justifiable with respect to the requirements that the business' nature, scale and risk place on the amount of equity, and the need for the company and the group, respectively, to strengthen its balance sheet, liquidity and position in other aspects.

Equity

The board of directors considers that the equity of the company and the group, respectively, will be of sufficient amount after the proposed acquisitions of own shares. The board of directors has in connection hereto considered the business' nature, scale and the risks that the business is associated with and the current economic situation, historical development and forecasts for the company and the group, respectively, as well as for the market.

Need of strengthening the balance sheet, liquidity and position in other aspects

The board of directors has made a comprehensive assessment of the company's and the group's financial position and their respective ability to fulfill its undertakings in the long term. As stated in the annual report for the 2019 financial year, the non-restricted equity of the company as per 31 December 2019 was EUR 435,998,934. As per the same date the group's total equity attributable to the shareholders of the company was approximately EUR 317,443,229.

The proposed acquisitions of own shares do not affect the company's or the group's ability to in due time fulfill its present and anticipated financial obligations or the ability to implement planned investments.

The board of directors has also considered other known matters that may affect the company's and the group's financial positions and that have not been considered within the scope of the above mentioned. No other matter that would make the proposed acquisitions of own shares unjustifiable has been identified during such analysis.

Stockholm in March 2020
Medicover AB (publ)
The board of directors